OraSure Technologies (NASDAQ: OSUR) and Sientra (NASDAQ:SIEN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and valuation.

Insider & Institutional Ownership

94.5% of OraSure Technologies shares are owned by institutional investors. Comparatively, 76.6% of Sientra shares are owned by institutional investors. 6.4% of OraSure Technologies shares are owned by company insiders. Comparatively, 28.1% of Sientra shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares OraSure Technologies and Sientra’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OraSure Technologies 20.48% 14.12% 12.57%
Sientra -169.77% -68.82% -43.13%

Earnings and Valuation

This table compares OraSure Technologies and Sientra’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OraSure Technologies $128.20 million 8.33 $19.72 million $0.52 33.85
Sientra $20.73 million 13.93 -$40.16 million ($2.85) -5.22

OraSure Technologies has higher revenue and earnings than Sientra. Sientra is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for OraSure Technologies and Sientra, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OraSure Technologies 0 1 4 0 2.80
Sientra 0 1 4 0 2.80

OraSure Technologies presently has a consensus target price of $17.25, indicating a potential downside of 1.99%. Sientra has a consensus target price of $13.75, indicating a potential downside of 7.59%. Given OraSure Technologies’ higher possible upside, analysts plainly believe OraSure Technologies is more favorable than Sientra.

Risk & Volatility

OraSure Technologies has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Sientra has a beta of -1.47, meaning that its share price is 247% less volatile than the S&P 500.

Summary

OraSure Technologies beats Sientra on 9 of the 11 factors compared between the two stocks.

About OraSure Technologies

OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company operates in two segments: OSUR and DNAG. OSUR consists of the development, manufacture and sale of diagnostic products, specimen collection devices, and medical devices. DNAG or molecular collection systems business consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing. It also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. It sells over-the-counter (OTC) cryosurgical products to consumers in North America, Europe, Central and South America, and Australia.

About Sientra

Sientra, Inc. is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons. Its breast implants are primarily used in elective procedures, which are generally performed on a cash-pay basis. TRUE Texture provides texturing on the implant shell that is designed to reduce the incidence of malposition, rotation and capsular contracture. The Company also offers breast tissue expanders and a range of other aesthetic and specialty products. The Company offers a range of HSC+ breast implants, including anatomically shaped textured, round textured and round smooth. The Company also offers miraDry system, the device to reduce underarm sweat, odor and permanently reduce hair of all colors.

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.